Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recurrent vulvovaginal candidiasis.

C MacNeill1, J C Carey

  • 1Division of Women's Health, Department of Obstetrics and Gynecology, Hershey Medical Center, 500 University Drive, Hershey, PA 17033, USA. cmacneill@psu.edu

Current Women'S Health Reports
|July 13, 2002
PubMed
Summary

Recurrent vulvovaginal candidiasis, often caused by non-albicans species resistant to antifungals, requires detailed diagnosis and prolonged treatment. Identifying host factors may enable targeted therapies for chronic pain syndromes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anthropocene survival of southern New England's salt marshes.

Estuaries and coasts : journal of the Estuarine Research Federation·2018
Same author

Contrasting decadal-scale changes in elevation and vegetation in two Long Island Sound salt marshes.

Estuaries and coasts : journal of the Estuarine Research Federation·2018
Same author

Author Correction: Crowther et al. reply.

Nature·2018
Same author

Crowther et al. reply.

Nature·2018
Same author

Quantifying global soil carbon losses in response to warming.

Nature·2016
Same author

Bone resorption in syndromes of the Ras/MAPK pathway.

Clinical genetics·2011

Area of Science:

  • Mycology
  • Infectious Diseases
  • Women's Health

Background:

  • Over-the-counter antifungal use has increased recurrent vulvovaginal candidiasis (RVVC) cases.
  • RVVC is linked to chronic vulvovaginal pain syndromes.
  • Non-albicans Candida species are increasingly implicated in RVVC.

Purpose of the Study:

  • To highlight the diagnostic challenges and therapeutic needs in RVVC.
  • To emphasize the importance of accurate species identification for effective treatment.
  • To discuss the role of prolonged antifungal therapy and future research directions.

Main Methods:

  • Review of current literature on vulvovaginal candidiasis diagnosis and treatment.
  • Analysis of the increasing prevalence of non-albicans Candida species.
  • Discussion of antifungal resistance patterns and therapeutic strategies.

Main Results:

  • Non-albicans Candida species are frequently resistant to standard azole antifungals.
  • Accurate species identification via fungal culture is crucial for appropriate treatment.
  • Long-term suppressive therapy (≥6 months) is often necessary for managing RVVC.

Conclusions:

  • Aggressive, diagnosis-driven therapy is essential for RVVC and associated pain syndromes.
  • Fungal cultures are vital for identifying non-albicans species and guiding treatment.
  • Further research into host factors may lead to personalized therapies for RVVC recurrence.

Related Experiment Videos